OIS@AAO 2016 Videos

New to the anterior segment arena, Z Lens was founded by Paul Beer, MD, and Edward Eveleth. Dr. Beer has more than 28 years’ experience…

Avedro’s chief medical officer, Rajesh K. Rajpal, MD, said 2016 marked the first US Food and Drug Administration approval of a collagen cross-linking (CXL) device,…

Appellis CEO Cedric Francois delivered an update on his company’s fully enrolled Phase III Filly trial of APL-2, a peptide targeting the C3 inhibitor in…

Paul Chaney, president and CEO, PanOptica, brought the OIS@AAO crowd up to speed on the progress of PAN-90806, a topical eyedrop for the treatment of…

Jason Slakter, CEO, Ohr Pharmaceutical, told OIS@AAO attendees that the company is enrolling patients in a Phase III clinical trial to test the efficacy of…

CHICAGO—Inotek is committed to “transforming glaucoma treatments,” David Southwell, president and CEO, said here during the Ophthalmology Innovation Summit. Glaucoma is a $5.6 billion worldwide…

CHICAGO—QLT, a biotechnology company, is focused on developing its synthetic retinoid program for the treatment of certain inherited retinal diseases, said David Saperstein, MD, chief…

Jeffrey Cleland, president and CEO, Graybug Vision, reports progress on its two treatments for wet age-related macular degeneration (wet AMD) and glaucoma. The company is…

Ocular Therapeutix entered into a collaboration with Regeneron Pharmaceuticals to develop a sustained-release formulation of Eylea (aflibercept), Ocular Therapeutix president, CEO, and chairman Amar Sawhney,…

Joseph Gardner, president and CEO of Aerpio Therapeutics, acknowledged that his company is not alone in developing Tie2-activating agents to treat retinal disease, but at…

Early reports of AGTC’s lead gene therapy program for X-linked retinoschisis have shown the treatment to be well-tolerated with only mild-to-moderate inflammation that either resolves…